Introduction
Establishing effective anti-epileptic therapy is particularly important for people with intellectual disabilities. People with an intellectual disability have an increased prevalence of epilepsy compared to the general population with rates reported in the literature ranging from 14% to 44%. 1 Prevalence increases with severity of intellectual disability 1 and, in addition to the increased prevalence of epilepsy, there is an increased prevalence of refractory epilepsy requiring polytherapy/add-on therapy. Epilepsy in this population is associated with increased morbidity and mortality, 2 partly because it is associated with other co-morbidities and increased risk of death from respiratory causes. 3 The mortality risk for the population with epilepsy and intellectual disability has been shown to be five times that of the general population whilst the risk ratio for people with intellectual disabilities without epilepsy is only 1.6. 4 Presence of intellectual disability increases the likelihood of sudden unexplained death among people with epilepsy, 5 due partly to the poorer control of epilepsy and an increased susceptibility to post-ictal apnoea and positional asphyxia. 6 Alongside the awareness of the special nature of epilepsy in people with an intellectual disability, it is recognised that the evaluation of treatment outcome needs a distinctive focus. 7, 8 Seizure reduction remains a primary endpoint but other variables are important. These include the impact of epilepsy and its treatment on quality of life and on potentially related issues such as patterns of behaviour. Evidence based guidelines have been produced for the management of epilepsy among people with intellectual disabilities. 9 However, these recognise the paucity of evidence specific to this population. Gaining an appropriately specific evidence base for treatment intervention is an ethical requirement, a concern which has been articulated more generally in relation to this population.
Purpose: To investigate the efficacy and safety of levetiracetam in adults with intellectual disabilities who have uncontrolled partial or generalised epilepsy.
Methods: An open label prospective study compared seizure frequency, adverse effects, participant challenging behaviour, carers' concerns about epilepsy and perceived participant quality of life between a baseline observation prior to the use of levetiracetam and follow-up observations at 3, 6, 9 and 12 months afterwards. Challenging behaviour, carers' concerns about epilepsy and perceived quality of life were assessed using standardized measures.
Results: Recruitment was low (n = 42). Six participants did not enter the trial. Two participants withdrew at initiation of treatment, one with seizures worsening and one with a rash, and a further one later on with a rash; all were felt to be drug related. Three other participants withdrew for independent reasons. Twelve months follow-up was achieved for 26 participants (62%) and at least 6 months follow-up for 30 participants (71%). Median seizure frequency reduced from baseline levels of 4.2 per week to average post-intervention levels of 2.2 for the 30 participants (z = À2.53, p < .05). No overall change in challenging behaviour was found, although increases in behaviour problems were reported for a minority. Patient concerns about seizures and medical treatment declined and perceived quality of life relating to seizure severity improved whilst that related to behaviour deteriorated. Increased adverse effects were reported immediately after initiation of levetiracetam but declined towards baseline levels by study completion. Discussion: Conclusions must remain tentative due to methodological weaknesses. Further investigation of the possible changes found here within a controlled study is merited. In brief, the aim was to conduct a prospective, multi-centre, open label study to investigate the efficacy and tolerability of levetiracetam as an add-on therapy for adults with intellectual disabilities who have uncontrolled partial or generalised epilepsy. Efficacy was assessed in terms of seizure frequency, carers' concerns about epilepsy and perceived participant quality of life. Participant challenging behaviour was assessed as a potentially related outcome and also as a specific aspect of safety. Adverse effects were monitored. Adults with intellectual disabilities who had partial or primary generalised seizures refractory to current treatment were recruited from clinics in the United Kingdom. Prospective baseline observations prior to the introduction of levetiracetam (T 1 ) were compared to follow-up observations at 3, 6, 9 and 12 months afterwards (T 2 -T 5 ).
Methods

Participants
The intention was to recruit at least 100 participants from 15 centres in the United Kingdom. Criteria for inclusion were (a) being 18 years of age or over, (b) having an intellectual disability identified by the investigator, and (c) having partial or primary generalised seizures with a minimum of 2 seizures/month over the 8 weeks baseline period (seizure clusters not excluded). Exclusion criteria were: (a) being aged under 18 years, (b) not having a diagnosis of intellectual disabilities, (c) a known contra-indication to levetiracetam, (d) use of levetiracetam in the previous 2 years, and (e) being female with a high probability of becoming pregnant. Participants were able to withdraw from the study at any time.
In the event, only 42 participants were recruited from 5 centres. Under-recruitment was due to failure to gain the necessary collaboration from other centres, which had expressed an interest to participate, to follow the study protocol and collect the necessary measures. Six of the 42 participants recruited did not start medication and, therefore, were not part of the trial. Characteristics of the 36 people exposed to the medication are given in Table 1 . A further 6 were excluded for the following reasons: 3 withdrew early in the study for reasons unconnected to the medication such as ill health or bereavement in the family, 2 withdrew prior to T 3 due to adverse reactions to the medication and 1 participated throughout but had no baseline data collected. Thirty participants received the medication change and had baseline and at least 6 months follow-up data collected (i.e., up to and including T 3 ). Data collection beyond this was partial for 4 participants, one of whom withdrew due to a rash believed to be associated with the medication. Characteristics of the 30 participants with 6-12 months follow-up are also set out in Table 2 .
Intervention
Participants received levetiracetam as an add-on therapy. Speed of initiation and dosage were determined by the physician. Dosages of levetiracetam and the number of other anti-epileptic drugs (AEDs) taken by participants throughout the study are given in Table 2 .
Procedure and measurement
Multi-centre research ethics approval was gained in 2002 (MREC/02/7/67). Local ethical approval was gained for each participating centre together with Trust R&D approval. Informed consent was gained from the patient or, if this was not possible, assent was obtained from family or carer.
Data were collected at baseline (T 1 ), 2 months prior to the introduction of the medication change detailed above, and for four three-monthly follow-up points (T 2 -T 5 ). Information on the following participant characteristics was obtained at T 1 from a carer who knew the participant well: age, gender, medical history, diagnosis, seizure types, anti-epileptic drug (AED) therapy, other concomitant therapy, adaptive behaviour and challenging behaviour. The main outcome measure was the frequency of seizures. This was assessed over a prospective 2 months baseline period (T 1 ) and for four post-intervention 3-month periods (T 2 -T 5 ). Change in challenging behaviour was also assessed as a potential outcome, at T 1 and at each of T 2 -T 5 . At the same times, data were collected on anti-epileptic medication, concomitant therapy, carer's concerns about epilepsy and their perceptions of participant quality of life.
Information on age and gender, diagnosis, seizure types, AED therapy and other concomitant therapy was gained by the clinical team. Participant adaptive behaviour was assessed by using Part One of the Adaptive Behaviour Scale (2nd edition) (ABS), 11 which comprises 66 items spanning 10 domains of functioning. Internal consistency coefficients averaged across age groups for the 10 domains range from .81 to .99 and correlation coefficients for testretest reliability from .88 to .99. 11 Higher scores indicate greater independence. Adequate levels of item discrimination, criterionrelated validity and construct validity are also reported. 11 A total ABS raw score was calculated by combining the domain scores. Domain scores were converted to percentile rank scores and these were averaged to gain a percentile rank equivalent of the total raw score. Participant challenging behaviour was assessed by using the Aberrant Behavior Checklist (ABC). 12 The ABC comprises 58 behaviours, each relating to one of five subscales: irritability, hyperactivity, lethargy, stereotypy and inappropriate speech. High scores indicate more or more severe challenging behaviour. The authors report internal consistency coefficients for the five subscales ranging from .86 to .94, correlation coefficients for test Table 1 Characteristics of the participants exposed to medication (n = 36) and those (n = 30) with 6-12 months follow-up data. 
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-retest reliability from .96 to .99, and correlation coefficients for inter-rater reliability from .55 to .69. Frequency of seizures was measured by carers keeping a seizure diary. This comprised a series of formatted sheets, each covering a period of 1 week. Informants recorded the number of seizures across pre-specified seizure types each day, along with any comments (e.g., contextual information) and perceived adverse effects of medication (e.g., symptoms and their severity). Diaries were designed individually with personalised descriptions of seizure types to guide recording. Overall, nine seizure types were monitored: complex partial, secondary generalized tonic clonic, generalized tonic clonic, atonic, myoclonic, tonic, absences, simple partial and unclassified. Diaries were kept for a prospective 2-month baseline period prior to intervention (T 1 ) and for 4, 3-month periods subsequently (T 2 -T 5 ).
Carer concerns about epilepsy were obtained by using the Glasgow Epilepsy Outcome Scale (GEOS). 13 This is a scale with 35
items each rated on a scale of 0-4, with 0, never a concern/not applicable; 1, occasionally a concern; 2, fairly often a concern; 3, often a concern; 4, very often a concern. The 35 items divide into four subscales: Concerns about seizures (10 items), concerns about medical treatment (9 items), concerns about caring for a person with epilepsy (8 items) and concerns about the social impact of epilepsy (8 items). Subscales have strong internal consistency (0.89 a ! 0.91).
Carer perceptions of participant quality of life were obtained using the Epilepsy and Learning Disabilities Quality of Life Questionnaire (ELDQOL).
14 The final version of ELDQOL includes 70 items covering seizure severity, seizure related injuries, antiepileptic drug side effects, behaviour, mood, physical functioning, cognitive functioning, social functioning, parental concerns, communication, overall quality of life and overall health. Items in the behaviour (n = 9), seizure severity (n = 14), mood (n = 16) and side effect (n = 19) domains are summed to create four subscales. Remaining domains consist of single or several nonsummed items. The four subscales were shown to have good internal consistency (a = .74-.95) and test-retest reliability (.80-.92). An earlier, slightly different version than the one to be published was used in this study. It produces the four subscales described above. Other individual items relate to perceived seizure control, health, quality of life and parental concerns. It is important to note that the behaviour subscale is not synonymous with challenging behaviour but relates more to positive social interactions and activities of daily living such as bowel habit or sleep.
Analysis
Frequencies of seizures were calculated per week based on the actual intervals between data collection points. Frequencies of occurrence across different seizure types were summed at each time point to obtain a total seizure frequency. Analysis was also performed on the total minus absence and myoclonic seizures as it was felt that, such were the problems in recording these seizures, their presence may affect the results. For both of these summary variables and for each seizure type separately, the mean postintervention seizure frequency was calculated. This was done by summing T 2 -T 5 measures and dividing by 4 for the 26 participants with complete 12 months follow-up datasets, and by summing T 2 and T 3 measures and dividing by 2 for the additional 4 participants with only 6 months follow-up data. Other outcomes (ABC, GEOS and ELDQOL) were treated similarly. Changes from baseline to the mean post-intervention were investigated, as also were changes to the last post-intervention data point. In addition, those participants who had mean post-intervention seizure frequencies at least 50% below baseline levels were identified.
The analysis approach described above was adopted because no follow-up data were obtained for those participants who withdrew from the study for reasons either related or unrelated to the medication change. An intention-to-treat analysis would conventionally be based on all 36 participants who entered the trial. Such an analysis could only be undertaken here by replacing missing data. In order to explore the potential bias due to only analysing change in seizure frequency for those who reached at least the half-way point of the trial, an intention-to-treat analysis was conducted by (a) carrying forward the baseline seizure frequency data for the 4 participants who withdrew before T 2 , (b) carrying forward the T 2 seizure frequency data for the participant who withdrew between T 2 and T 3 and (c) using the T 2 data for the T 1 point for the participant for whom no baseline data were collected. An additional analysis was also undertaken based on 33 participants, excluding only the 3 who withdrew for reasons unrelated to the medication. In both cases, all changes in seizure frequency explored reached statistical significance. This was not the case for the analysis approach adopted, as is made clear below. The increase in sample size in moving to the intention-to-treat analysis outweighed the addition of cases with no pre-post change in the calculation of statistical significance. The analytic approach presented is the more conservative.
The normality of the data for each outcome variable at each data collection point was tested using a series of Kolmogorov-Smirnov tests. The great majority were highly significant, indicating substantial departure from normality. Non-parametric tests of difference (Wilcoxon signed ranks test) or correlation (Spearman's rank correlation coefficient) were, therefore, used throughout. The median is given in the results section as the most meaningful indicator of central tendency.
Results
Seizure frequency
Changes in seizure frequencies from baseline are given in Table 3 . All figures referring to seizure frequency are the average number of occurrences per week. Total seizure frequency significantly reduced (z = À2.53, p < .05 to post-baseline mean, z = À3.75, p < .001 to last data point). Degree of change was similar with absences and myoclonic seizures removed. There were 13 participants whose mean post-intervention seizure frequency was 50% of the baseline level or less. They changed from a baseline median frequency of 7.8 to a mean post-intervention median frequency of 1.5. Two participants became seizure free after the introduction of levetiracetam. One participant had a substantially increased seizure frequency by the end of the study (18.5) a The zero reflects participants ceasing to take the drug who were followed up for the first 6 months. b The zero reflects participants who ceased to take the drug at the last data point.
compared to baseline (6.6). Three other participants had increases of less than one seizure per week. Reduction in complex partial seizures (n = 14) and secondary generalized tonic clonic seizures (n = 5) was greater than in generalized tonic clonic seizures (n = 18), atonic seizures (n = 5), myoclonic seizures (n = 5), primary generalized tonic seizures (n = 5), absence seizures (n = 8) or simple partial seizures (n = 3).
Challenging behaviour, concerns about epilepsy and perceived quality of life
Total ABC scores did not change (see Table 4 ). There was also no change on any of the five subscales. Neither was there an association between the total frequency of seizures and total ABC score at any time point nor the change in the total frequency of seizures and change in total ABC score between baseline and the average post-intervention.
A number of GEOS questionnaires at each time point had one or two items which were not completed. Which participants were affected varied across time points so that the potential impact of missing data on the calculation of subscale and total scores was considerable. A decision was, therefore, taken to replace missing data by the average for the item and restrict comparison to the 26 participants for whom 12 months follow-up was achieved. Total scores on the GEOS significantly declined, as did two subscale scores: concerns about seizures and concerns about medical treatment (see Table 4 ). The two remaining subscales, concerns about caring for a person with epilepsy and concerns about the social impact of epilepsy, did not change.
Missing data on the ELDQOL meant that analyses were restricted to 27 participants (see Table 4 ). Scores on the behaviour subscale deteriorated and the seizure severity subscale improved. Otherwise, there were no other significant subscale changes. In relation to individual items, the only item to change significantly was a lessening of parental concerns (baseline median = 3.0, average post-intervention median = 2.0, z = À2.40, p < .05).
Adverse effects
As reported above, there were 42 participants recruited. Six did not start medication; 36 people were exposed to the medication. Five people withdrew after baseline but before either the T 2 or T 3 data collection round. There were no safety issues for three of these participants; reasons for withdrawal were unconnected to the medication. The other two experienced early adverse effects believed to be related to levetiracetam, which comprised deterioration in seizure control and a rash. Table 5 sets out adverse effects reported for the remaining 31 participants who were followed up for at least two post-intervention data points (including the person who was excluded from the analysis to this point as no baseline data were collected). One of these 31 participants withdrew from the trial after T 3 because of a rash attributed to the medication. No adverse effects were reported for 11 of the 31 participants (35%) at any time during the study. Adverse effects were reported for 5 participants at T 1 (17%). Adverse effects continued to be reported for these 5 participants at subsequent data points, that is, after the addition of levetiracetam. For 2 of these 5 people, subsequent adverse effects were broadly similar to those at baseline, for 2 they appeared to change, and for one there was a mixture of continuation and change. Adverse effects began to be reported for 15 participants from T 2 onwards (48%). As can be seen from Table 5 , there was an increase at T 2 in reporting of fatigue, behaviour problems, digestion problems and a variety of physical problems. The number of participants reporting adverse effects was greatest at T 2 (18), thereafter declining. Adverse effects continued to be reported by 7 participants at T 5 , the 5 participants at T 1 and 2 others.
No adverse effects were reported for 67% of participants with higher levels of challenging behaviour at the outset of the study (i.e., those with ABC scores above the median). However, the two participants for whom challenging behaviour was reported as an adverse effect at the last data point were amongst this subgroup. Such behaviour had been first reported for one participant at T 2 (i.e., after introduction of levetiracetam). Otherwise, levetiracetam appeared to be well tolerated by this subgroup.
Discussion
This study was an open label uncontrolled trial and, as such, one can only reach tentative conclusions relating to treatment effects. In addition, there is sparse information about other treatment changes, which may have co-occurred with the change of medication under investigation. Therefore, a more definitive conclusion must await a more rigorous trial. Such a trial appears Table 3 Median seizure frequencies at baseline, mean post-intervention and at the last postintervention data point, and significance of change. Table 4 Median baseline and mean post-intervention scores on the GEOS and ELDQOL, and significance of change. justified as the indications here are that adding levetiracetam to current medication was found to be associated with a reduction in total seizure frequency, limited alteration in challenging behaviour and improvement in carer concerns about the effects of seizures and medical treatment. In addition, some aspects of perceived quality of life appeared to improve. Adverse reactions were experienced early. These either led to immediate drug discontinuation or reduced with time. Before expanding on these findings, it is important to discuss a number of other weaknesses which affect interpretation. Multiple testing gives rise to a danger of Type 1 error, namely the acceptance of a difference as real when it may reflect chance variation. In relation to reduction in seizure frequency, we have restricted ourselves to testing the overall change in total seizure frequency. We have also tested for change in five areas of the GEOS and four areas of the ELDQOL. It is possible that there is some risk of Type 1 error in these analyses. There was a reduction in overall seizure frequency which was accompanied by lowered carer concern about seizures and medical treatment and improved quality of life on the seizure severity subscale. There was no great evidence of randomly occurring significant differences found outside this cluster of findings; more general concerns and quality of life issues remained unaltered.
The under-recruitment in the sample gives rise to a greater likelihood of making Type 2 error, that is concluding that a real difference is only due to chance. Changes would be more clearly demonstrated in a study with a larger sample of the size originally planned.
The sample was not drawn at random and its representativeness is not known. In addition, there was no control group and hence no control for maturation, history or regression to the mean, should presentation at clinic for drug review have been precipitated by a period of increased occurrence of seizures. Therefore, caution must be exercised in attributing the changes observed to the change in medication. However, in relation to maturation, participants were drawn from a population who have characteristically experienced seizures refractory to treatment for a long time. That seizure frequency should reduce spontaneously is somewhat unlikely. In relation to history, it is a weakness that information on concomitant therapy is imprecise. However, the information which was collected and presented in Table 2 indicates that the prescription of other AEDs remained at a consistent level throughout the study. Regression to the mean from an atypically high seizure frequency which may have prompted presentation for drug review is another concern. Here, the study at least has the merit of a prospective baseline seizure frequency measured over a period of 2 months before medication change.
Seizure control
Numerous studies have shown the anticonvulsant properties of levetiracetam, so it is not particularly novel for this study to have shown improved seizure control associated with the introduction of this medication. However, studies of people with an intellectual disability are less common and, when reported, tend to summarise seizure control generally in terms of ''responders'' and ''nonresponders'' rather than to quantify change in seizure frequency as done here. Seizure change was found for complex partial and secondary generalized tonic clonic seizures. The numbers are small and analysis should be cautious. However, the absence of significant change in more generalised epilepsies is consistent with the refractory nature of epilepsy among people with intellectual disability. Seizure deterioration was limited unlike other studies. 15 
Challenging behaviour
Family or carer concerns about behaviour change as a result of epilepsy treatment are commonly encountered in clinical practice. We believe our study to be the first on levetiracetam which has used a well-validated population appropriate measure of behaviour disorder. Unlike the findings of Hurtado et al., 16 this study showed no significant general alteration in challenging behaviour. The lack of consistency between the two studies may be due to differences in definition of challenging behaviour and how challenging behaviour was measured. However, ABC scores did rise for some individuals. There were 8 participants for whom Table 5 Reported adverse effects of pre-existing anti-epileptic drugs (AEDs) (T 1 ) and preexisting AEDs together with levetiracetam (T 2 -T 5 ).
Side effect Number of participants reporting side effect (n = 31) behavioural or emotional adverse effects were reported. ABC scores increased after medication for 4, went down for 2 and stayed at broadly the same low level for the other 2. Care needs to be taken about impact on challenging behaviour among a minority of recipients.
Concerns about epilepsy and perceived quality of life
The significant lessening of carer concern relating to seizures and treatment would appear to reflect the impact on seizure control. The other two subscales, concerns about caring for a person with epilepsy and concerns about the social impact of epilepsy, have items which are more general in nature. It is probably unrealistic that short-term reduction in seizure frequency not leading to seizure freedom would be able to influence these variables. However, it is possible that longer term experience of reduced seizure frequency could lead to reduced concern. A similar distinction would appear reasonable in relation to the significant improvement in perceived quality of life relating to seizure severity compared to the absence of change in more general social or developmental issues. Understanding the negative effect on perceived adaptive functioning apparent in the change in the ELDQOL behaviour subscale is more complicated. The subscale reflects parental/carer perceptions over such issues as alertness, awareness, concentration, expression of wants and understanding, as well as physical functioning in terms of sleep quality and bladder/bowel control. Deterioration may reflect the increase in reported adverse effects concerning fatigue, sleepiness, digestion problems and a variety of physical problems. However, although these reported adverse effects reduced with time, the deterioration in the behaviour subscale did not reverse.
Adverse effects
The ability to explore treatment emergent adverse effects was a major aim. In order to achieve this, retention, challenging behaviour, perceived adverse effects and diary recorded adverse affects were addressed. At T 5 , 27 out of the 36 participants exposed to the drug (75%) remained on medication (the 26 participants with full 12-month follow-up and the one who was excluded due to absence of baseline data); 3 (8%) withdrew for what were believed to be drug related adverse effects. No general change was found in challenging behaviour as assessed by the ABC or in perceived adverse effects, as reflected in the ELDQOL side effects subscale. Diary recorded adverse effects showed a pattern of increased concerns immediately following the addition of the drug reducing over time to a level only slightly above baseline. Reported increases in behaviour problems matched by increased postintervention ABC scores were found for a minority (13%).
Conclusions
This study has shown that levetiracetam could be a useful addon therapy for epilepsy among people with intellectual disabilities. On the basis of these findings, its use is likely to lead to some seizure reduction with only limited impact on challenging behaviour. Serious adverse effects are uncommon, tend to attenuate with time or can be managed by drug withdrawal. Clinicians should observe for these, expect some early treatment effects and be prepared to support carers and individuals in responding to concerns raised during treatment.
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